| 王 俊,冉凤鸣,胡 胜,等.广泛期小细胞肺癌一线免疫治疗的现状及研究进展[J].肿瘤学杂志,2025,31(12):1028-1035. |
| 广泛期小细胞肺癌一线免疫治疗的现状及研究进展 |
| Research Progress of First-Line Immunotherapy for Extensive-Stage Small Cell Lung Cancer |
| 投稿时间：2025-01-09 |
| DOI：10.11735/j.issn.1671-170X.2025.12.B004 |
|
 |
| 中文关键词: 癌，小细胞肺 广泛期 一线治疗 免疫治疗 |
| 英文关键词:carcinoma, small cell lung extensive-stage first-line treatment immunotherapy |
| 基金项目:湖北省自然科学基金面上项目（2022CFB550）；湖北省中医药管理局2023~2024年度中医药面上项目（ZY2023M14）；希恩科—艾力斯肺癌靶向治疗研究基金项目（Y-2021AST19n-0088）；湖北省肿瘤医院医院人才项目（2025HBCHQHRC016） |
|
| 摘要点击次数: 0 |
| 全文下载次数: 3 |
| 中文摘要: |
| 摘 要：广泛期小细胞肺癌（extensive-stage small cell lung cancer，ES-SCLC）是一种恶性程度高、侵袭性强和预后差的恶性肿瘤。传统的化疗方案虽能在一定程度上缓解病情，但长期生存率仍不理想。近年来，免疫治疗改变了ES-SCLC的治疗格局。目前免疫治疗联合化疗已成为ES-SCLC一线治疗的标准方案。然而，由于免疫治疗联合化疗带来的生存获益仍然有限，如何进一步提高一线治疗的疗效仍是亟待解决的问题。全文系统总结ES-SCLC一线免疫治疗的现状、研究进展以及面临的挑战，为临床诊疗提供参考。 |
| 英文摘要: |
| Abstract： Extensive-stage small cell lung cancer (ES-SCLC) is a highly aggressive cancer characterized by rapid progression， early metastasis， and poorly prognosis. While conventional platinum-based chemotherapy regimens can provide initial disease control， long-term survival rates remain suboptimal. In recent years， the emergence of immunotherapy has revolutionized the therapeutic landscape for ES-SCLC. Currently， the combination of immune checkpoint inhibitors (ICIs) with platinum-etoposide chemotherapy has become the first-line standard treatment regimen for ES-SCLC. However， given the limited survival benefit achieved through the combination of immunotherapy and chemotherapy， the question of how to further enhance the efficacy of first-line treatment remains an urgent challenge that requires immediate attention. This paper summarizes the current status， research advancements， and challenges associated with first-line immunotherapy for ES-SCLC， thereby providing a valuable reference for clinical diagnosis and treatment. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |